Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Deals

Jiangsu Hengrui Pharmaceuticals Launches Hong Kong IPO of H-Shares

Fineline Cube May 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has officially launched an initial public offering...

Company Deals

CSPC Pharma Licenses Irinotecan Liposome Injection to Cipla for US Market

Fineline Cube May 15, 2025

China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has entered into a licensing agreement with India-headquartered...

Company Drug

WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure

Fineline Cube May 15, 2025

China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National...

Others

AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics

Fineline Cube May 15, 2025

US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals,...

Company Medical Device

Roche’s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients

Fineline Cube May 15, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA®...

Company Deals

Novo Nordisk and Septerna Ink $2.2 Billion Deal for GPCR Drug Discovery

Fineline Cube May 15, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) and Septerna, Inc. (NASDAQ: SEPN) announced an exclusive...

Company

Sanofi Announces $20 Billion Investment in US R&D and Manufacturing by 2030

Fineline Cube May 15, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its intention to invest at least $20...

Company Deals

GSK Signs Deal to Acquire Boston Pharmaceuticals’ Efimosfermin Alpha

Fineline Cube May 14, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP...

Company Deals

Acchrom Technologies Secures Pre-Series B Funding to Expand Chromatography Solutions

Fineline Cube May 14, 2025

Beijing-based Acchrom Technologies Co., Ltd., a specialist in chromatography, has reportedly secured over RMB 100...

Company Deals

Ningbo Jansen Files STAR IPO for MRI Technology Expansion

Fineline Cube May 14, 2025

China-based Ningbo Jansen NMR Technology Co., Ltd. announced that its initial public offering (IPO) filing...

Company Drug Medical Device

China’s Q1 2025 Pharmaceutical Exports Rise 4.39% Despite Import Decline

Fineline Cube May 14, 2025

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Porton Pharma Collaborates with Henan Hualong for MATC Therapy Development

Fineline Cube May 14, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has entered into a...

Company

Bayer Reports Flat Q1 Revenue amid Crop Science Decline

Fineline Cube May 14, 2025

German pharmaceutical and chemical giant Bayer (ETR: BAYN) released its Q1 2025 financial report, recording...

Company Drug

Medilink Therapeutics Gains FDA IND Approval for VEGF-Targeted ADC YL242

Fineline Cube May 14, 2025

Suzhou-based Medilink Therapeutics announced that it has received Investigational New Drug (IND) approval from the...

Company Drug

Zhongsheng Pharma’s Anruiwei Shows Promising Results in Pediatric Influenza A Study

Fineline Cube May 14, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the topline analysis data from the...

Company Drug

Sinovac Biotech Gains Hong Kong Approval for Influenza Vaccines

Fineline Cube May 14, 2025

China-based Sinovac Biotech Ltd (NASDAQ: SVA) announced that it has received marketing approvals from the...

Company

InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable

Fineline Cube May 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording...

Drug Policy / Regulatory

NMPA Releases 92nd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube May 14, 2025

The National Medical Products Administration (NMPA) has released the 92nd batch of reference drugs for...

Company Deals

Gan & Lee Pharmaceuticals Signs PDP Agreement with Brazilian Health Ministry

Fineline Cube May 14, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced the signing of Parcerias para o Desenvolvimento Produtivo...

Company Drug

Zelgen Biopharmaceuticals Submits New Indication Application for Jacktinib in Severe Alopecia Areata

Fineline Cube May 14, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has submitted a new...

Posts pagination

1 … 163 164 165 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.